An observational study in Hypertension, Dyslipidemia, sponsored by GC Biopharma Corp. Active, not recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-07-24.
Sponsored by GC Biopharma Corp · Observational
The purpose of this study is to evaluate the effectiveness and safety of the investigational drug on blood pressure and LDL cholesterol control during the observation period in patients who have undergone percutaneous coronary intervention (PCI) in actual clinical practice.
This study is a multicenter, prospective, non-interventional observational study aimed at observing the efficacy and safety of the investigational product, a combination of telmisartan, rosuvastatin, and ezetimibe, in patients who have undergone percutaneous coronary intervention (PCI) for the control of blood pressure and lipid levels.
In actual clinical practice, patients aged 19 years and older who have undergone PCI and are receiving antihypertensive and dyslipidemia-related medications based on approved indications will be assessed for eligibility after receiving an explanation of the study and providing written consent, as determined by the investigator's judgment regarding the need for the investigational product.
Eligible participants according to the inclusion/exclusion criteria will receive the investigational product based on the approved indications (efficacy, dosage, precautions, etc.) after registration. Follow-up visits will be conducted at 24 weeks and 48 weeks (each ± 4 weeks) post-treatment to evaluate efficacy and safety.
All treatments, including drug administration and laboratory tests performed after the administration of the investigational product, will be conducted according to the investigator's medical judgment, independent of the participant's involvement in the study, and information to be collected in this observational study will continue for up to 48 weeks (± 4 weeks).
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 1,563 is above the median of 210 across 1,359 observational studies indexed under Hypertension.
Browse Hypertension studies →GC Biopharma Corp is the lead sponsor of 14 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
A patient population with a history of undergoing PCI
1. Adults aged 19 years and older, both male and female. 2. Patients who have undergone percutaneous coronary intervention (PCI) and are receiving antihypertensive and dyslipidemia-related medications.
3. Individuals who require the administration of the investigational product based on the investigator's medical judgment in accordance with approved indications.
4. Individuals who can understand the information provided to them and are able to voluntarily sign the informed consent form.
Exclusion Criteria:
1. Individuals who fall under the contraindications for administration according to the approved indications of the investigational product.
2. Individuals who have a history of receiving the investigational product prior to participation in this study.
3. Individuals whom the investigator deems unsuitable for participation in this observational study for any other reason.
The proportion of participants who meet the treatment goals for BP and LDL-C
Time frame: From enrollment to the end of treatment at 24 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GC Biopharma Corp